Dive into the pulse of the microscopic world, explore synthetic evolutionary paths, and get better bio-tech insights.
The FDA approved Casgevy and Lyfgenia in December 2023, including the first FDA-approved CRISPR/Cas9 therapy for sickle cell disease in patients 12 and older.
Feb 22, 2026 • 1 likes • 1 comments
Researchers identified a new genetic alteration in ependymoma that may improve molecular diagnosis.
Get weekly discovery roundups in your inbox.
